Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

Novartis Pharmaceuticals602 enrolled

Overview

This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.

Study Type

OBSERVATIONAL

Enrollment

602

Conditions

Diffuse Large B-cell Lymphoma Acute Lymphoblastic Leukemia (ALL)

Eligibility

Sex: ALLMin age: 1 Year

Medical Language ↔ Plain English

Inclusion criteria: DLBCL population: * Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND * Diagnosed with DLBCL (International Classification of Diseases \[ICD-10 C833\]) when receiving CAR-T AND * Being 18 years of age or older. ALL population: * Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND * Diagnosed with ALL (ICD-10 C910) when receiving CAR-T AND * Being 25 years of age or younger. Exclusion criteria: DLBCL population: • Patients hospitalised with a diagnosis other than DLBCL during the historical period or during the index stay. ALL population: • Patients hospitalised with a diagnosis other than ALL during the historical period or during the index stay.

Locations (1)

Novartis

Rueil-Malmaison, France

Outcomes

Primary Outcomes

Number of medicine, surgery, obstetrics and odontology (MCO) stays per patient

Time frame: Up to 36 months

Number of outpatient visit (ACE) stays per patient

Time frame: Up to 36 months

Number of emergency room visits not followed by hospitalisation per patient

Time frame: Up to 36 months

Number of aftercare and rehabilitation (SSR) stays per patient

Time frame: Up to 36 months

Number of homecare (HAD) stays per patient

Time frame: Up to 36 months

Number of consultations per type of healthcare professional

Time frame: Up to 36 months

Number of consultations per patient (all consultations combined)

Time frame: Up to 36 months

Number of patients who died

Time frame: Up to 36 months

Cost of MCO hospitalisation

Time frame: Up to 36 months

Cost of CAR-T on the supplementary list

Time frame: Up to 36 months

Cost of medicines on the supplementary list (excluding CAR-T)

Time frame: Up to 36 months

Hospitalisation cost

Time frame: Up to 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.